Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

A grant from the Melissa Andrews Trust has funded a software update for the Pulmonary Function Test machine (PFT) at ...